Showing results (1441-1450 of 3,353) with videos related to

Sort By:
Pageof 336
Pharmacoeconomics|May 13, 2022
Evaluating the Individual Healthcare Costs and Burden of Disease Associated with RSV Across Age GroupsEllen Rafferty, Mike Paulden, Sarah A Buchan, et al.
Pharmacoeconomics|July 19, 2021
State of the ART? Two New Tools for Risk Communication in Health Technology AssessmentsSabine E Grimm, Xavier Pouwels, Bram L T Ramaekers, et al.
Pharmacoeconomics|June 3, 2021
The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in SwedenFredrik O L Nilsson, Sandra T Asanin, Elizabeth T Masters, et al.
Pharmacoeconomics|June 19, 2021
Jointly Modelling Economics and Epidemiology to Support Public Policy Decisions for the COVID-19 Response: A Review of UK StudiesAna Duarte, Simon Walker, Andrew Metry, et al.
Pharmacoeconomics|June 9, 2021
Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare PerspectiveDaniel Stellato, Marroon E Thabane, Jinhee Park, et al.
Pharmacoeconomics|April 7, 2020
Estimating the Value of New Antimicrobials in the Context of Antimicrobial Resistance: Development and Application of a Dynamic Disease Transmission ModelJason Gordon, Oliver Darlington, Phil McEwan, et al.
Pharmacoeconomics|November 30, 2020
Health State Utilities of Patients with Heart Failure: A Systematic Literature ReviewGian Luca Di Tanna, Michael Urbich, Heidi S Wirtz, et al.
Pharmacoeconomics|December 28, 2020
Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)Marwân-Al-Qays Bousmah, Marie Libérée Nishimwe, Tamara Tovar-Sanchez, et al.
Pharmacoeconomics|October 6, 2022
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP TrialEdna Keeney, Sabina Sanghera, Richard M Martin, et al.
Pharmacoeconomics|January 31, 2021
Modifying NICE's Approach to Equity WeightingMike Paulden, Christopher McCabe
Pageof 336